Loading clinical trials...
Loading clinical trials...
Phase II Clinical Study to Evaluate the Efficacy and Safety of WX-0593 in Patients With Crizotinib-resistant ALK -Positive, or Crizotinib-resistant/Crizotinib-naive ROS1-positive Non-small Cell Lung Cancer (NSCLC)
Conditions
Interventions
WX-0593 Tablets
Locations
41
China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Oncology Department, Anhui Cancer Hospital
Hefei, Anhui, China
Respiratory Department, Anhui Cancer Hospital
Hefei, Anhui, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Thoracic Oncology I Department, Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Start Date
March 7, 2019
Primary Completion Date
December 1, 2020
Completion Date
March 1, 2021
Last Updated
November 24, 2020
NCT06305754
NCT07190248
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions